ArticleHealth science reports2025
Immunoinformatics-Based Multi-Epitope Vaccine Design Against
Article in Health science reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- A bivalent multi-epitope vaccine targeting CSP and TRAP of Plasmodium vivax designed through immunoinformatics and structural bioinformatics.BMC microbiology · 2026Article
- Immunoinformatics-Based Multi-Epitope Vaccine Design AgainstHealth science reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aim: Malaria is an infectious disease that affects people in Africa, and other parts of the world by the millions. Despite the effectiveness of artemisinin-based combination therapies against the disease, current findings on possible Methods: In this study, we employ immunoinformatics and computational techniques to design a multi-epitope vaccine against Results: Collectively, the Tc cell and Th cell epitopes of the proposed vaccine cover an estimated 87.07% of the world's population, based on the HLA data set from the Allele Frequency Net Database. The vaccine construct was found to be soluble and have appropriate physicochemical properties. The docking, and molecular dynamics (MD) simulation studies carried out revealed strong and stable interactions between TLR4 and the vaccine construct. Immune simulation upon administration of the vaccine construct indicates the development of long-lasting memory B, and CD4+ T cells for antigen clearance. Conclusion: This computational study presents a promising multi-epitope subunit vaccine candidate against P. falciparum. The construct shows high population coverage, stability, and potential immunogenicity. These findings however require further experimental validations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.